DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo


2.46 -0.04 (-1.60%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $2.46 -1.60%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.49
Previous Close $2.50
Daily Range $2.46 - $2.52
52-Week Range $2.28 - $5.95
Market Cap $255.5M
P/E Ratio -3.13
Dividend (Yield) $0.00 (0.0%)
Volume 711,751
Average Daily Volume 2,330,674
Current FY EPS -$1.30




Drug Makers

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary Rss Feed

Arena Pharmaceuticals Inc.'s Plan to Win the Obesity Drug War

Building a better mousetrap.

Orexigen: Contrave Sales Pop, Equity Response Muted

Orexigen Has Contrave Recapturing Early-Year Form, But Needs European Launch

10 Most Hated Companies in Healthcare

When emotional trading is on display, the short-sellers come out to play. Find out which companies are the most hated in healthcare, why they're so universally disliked, and which company may eventually deserve a reprieve.

Orexigen - Contrave Sales Outpace Competition, But Are Still Not Enough

What Novo Nordisk's Entry Into The Obesity Space Means To The Sector

Orexigen Faces Generic Challenge For Anti-Obesity Drug

VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog

3 Promising Healthcare Stocks Under $10

Healthcare stocks with plenty of potential -- and low share prices

Vivus Sales Remain Flat - Stock Trend Not Good

See More VVUS News...

VVUS's Top Competitors

VVUS $2.46 (-1.60%)
Current stock: VVUS
JNJ $101.08 (0.62%)
Current stock: JNJ
NVS $104.28 (-1.16%)
Current stock: NVS
RHHBY $36.24 (-0.83%)
Current stock: RHHBY